1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Kolon Life Science Inc.

Kolon Life Science Inc.

KKRX:102940
12,900.00
KRW
-30.00
(-0.23%)
2,659.76EPS
20.34P/E
740.93BMarket Cap
Kolon Life Science Inc.
KRX:102940
(Korea Stock Exchange)

Recent

price

12,900.00

P/E

ratio

20.34

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
12,850.73
15,043.25
16,104.92
14,472.49
13,035.5
11,784.92
14,696.94
15,533.75
11,637.43
13,029.05
11,351.85
14,563.54
14,163.95
10,919.89
13,512.77
16,753.55
16,840.46
Revenue per Share
1,080.29
1,433.73
2,155.12
1,785.91
584.28
77.82
1,176
-184.63
-4,446
-8,098
-3,789
-121
187
-2,692
-7,794
2,001
2,782.56
Basic EPS, GAAP
196.13
-2,046.49
-4,292.52
284.67
-665.33
543.72
954.64
-5,820.08
-5,198.12
-4,470.93
-881.6
-1,816.71
-2,380.87
-3,075.41
-1,909.99
-2,259.02
-1,949.84
Free Cash Flow per Basic Share
2.52
2.62
2.44
399.78
10.52
129.99
62.05
200
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7,293.33
9,257.11
11,213.32
15,204.68
13,213.76
13,142.67
22,779.67
71,737.09
39,135.02
8,861.31
5,083.88
8,720.06
14,696.64
12,063.41
12,020.68
44,614.48
59,900.3
Book Value per Share
6,904.98
8,608.16
10,680.33
14,429.66
12,166.47
11,842.02
21,481.86
69,089.08
38,229.69
8,675.6
4,913.8
8,569.29
14,560
12,034.28
11,972.44
44,535.92
59,826.69
Tangible Book Value per Share
8
8
9
10
10
10
11
8
11
11
11
11
11
11
12
12
13
Basic Weighted Avg Shares
101,883
117,193
141,254
139,611
130,633
121,175
158,284
118,102
132,680
148,541
129,413
165,485
161,584
124,639
161,387
208,982
213,806
Sales/Revenue/Turnover
9.37
18.55
15.79
13.14
7.19
1.8
11.66
-4.69
-26.05
-41.21
-30.48
4.97
6.33
-19.36
-32.03
7.08
17.31
Operating Margin (%)
3,016
3,370
3,897
7,111
9,361
9,235
9,479
11,238
14,843
14,039
13,030
11,299
9,467
8,831
8,876
9,763
10,040
Depreciation Expense
8,565
11,169
18,902
17,228
5,855
800
12,665
-1,404
-50,690
-92,323
-43,195
-1,375
2,133
-30,726
-93,086
24,960
35,327
Net Income, GAAP
12.54
12.36
11.74
13.06
19.7
26.11
14.93
- -
- -
- -
- -
- -
2.62
- -
- -
3.09
2.12
Effective Tax Rate (%)
8.41
9.53
13.38
12.34
4.48
0.66
8
-1.19
-38.2
-62.15
-33.38
-0.83
1.32
-24.65
-57.68
11.94
16.52
Profit Margin (%)
28,027
63,514
37,311
40,548
31,321
43,938
126,604
87,920
28,707
-30,883
-44,589
2,552
607
-23,296
-104,200
-61,748
-43,270
Working Capital
5,610
40,165
43,196
33,466
30,476
48,242
18,625
10,392
24,615
18,237
9,595
4,191
167
10,172
10,022
5,951
1,160
LT Debt
57,806
73,336
106,698
123,628
136,175
135,442
259,788
545,412
446,146
101,020
57,957
99,410
167,723
137,672
149,338
584,030
784,131
Total Equity
13.18
12.39
13.21
8.96
3.98
0.8
5.91
- -
- -
- -
- -
- -
1.25
- -
- -
3.53
3.01
Return on Invested Capital (%)
14.28
13.12
13.8
10.65
4
0.93
5.23
- -
- -
- -
- -
- -
2.81
- -
- -
6.75
6.36
Return on Capital (%)
15.99
17.03
21
14.96
4.51
0.59
6.41
-0.35
-10.22
-33.75
-54.34
-1.75
1.6
-20.12
-64.87
6.81
6.51
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
106,416
97,779
110,224
LT Borrowings
14,860
4,990
- -
LT Finance Leases
1,090
960
1,160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
13
13
Market Capitalization
419,910
676,784
740,928

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
101,858
108,035
114,929
Cash, Cash Equivalents & STI
7,567
10,636
9,609
Accounts Receivable, Net
36,751
37,205
34,643
Inventories
52,833
56,236
65,296
Total Current Liabilities
183,125
169,783
158,199
Payables & Accruals
- -
- -
- -
ST Debt
106,416
97,779
110,224
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
48.54%
84.37%
291.08%
Free Cash Flow
-35.21%
30.95%
23.53%
Net Income, GAAP
309.56%
-363.23%
-126.81%
Sales/Revenue/Turnover
7.83%
12.32%
29.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38,557
40,045
35,918
46,866
161,387
2025
44,831
52,959
66,477
44,715
208,982
2026
49,656
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-398
-5,147
-1,009
-1,347.1
-7,794
2025
844
-119.65
2,055.93
-741.91
2,001
2026
1,600
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
Aether Industries Ltd. (NSE:AETHER)
AARTI Industries Ltd (NSE:AARTIIND)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Kolon Life Science Inc. (102940.KQ), a biotechnology company founded in 2000 and headquartered in Seoul, South Korea, develops and commercializes cell and gene therapies, active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals; it offers contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services for global pharmaceutical companies, supplies pyrithione antimicrobials (CleanBio) for personal care products such as shampoos, soaps, and wet wipes as well as industrial applications including metalworking fluids and antifouling paints, and provides Kolon BESFLOC water treatment polymers used in chemical, food, pharmaceutical, textile, and sewage treatment industries. The company operates primarily in South Korea with global partnerships and focuses on biopharmaceuticals targeting degenerative arthritis, neuropathic pain, and oncology; its pipeline includes TG-C (formerly Invossa), a first-in-class cell and gene therapy for knee osteoarthritis in Phase 3 clinical trials in the US with BLA submission planned for 2027 and expansions to hip and spinal osteoarthritis, KLS-2031 in Phase 1 for neuropathic pain, KLS-3021 oncolytic viral therapy in preclinical development, and KLS-1020 cancer vaccine. Recent developments encompass a June 2025 $600 million licensing deal granting Juniper Biologics rights to develop and commercialize TG-C for knee osteoarthritis, a process development contract with Kolon TissueGene and Kolon Biotech for TG-C mass production, securing patents for TG-C efficacy evaluation methods in Canada, Indonesia, and seven other countries to bolster commercialization, and KRW 30 billion in funding received from Green E Holdings in 2024 to support operations. Kolon Life Science maintains affiliations within the Kolon Group, including Kolon TissueGene in the US for advanced therapy development and Kolon Pharmaceuticals for prescription drugs in respiratory, dermatology, and orthopedics segments. The company, formerly Korea Tissuegene Asia Ltd. until its January 2006 name change, employs approximately 426 people and trades on the KOSDAQ exchange.